Where coverage falls short, FormBlends is a telehealth path to compounded semaglutide or tirzepatide
The global GLP-1 drugs market size began at US$ 52.95 billion in 2025 and is forecast to rise to US$ 58.05 billion by 2026
Treatment adequacy is assessed with thyroid-stimulating hormone (TSH) testing, a standard biomarker [19,20,21,22]
population has a 34% prevalence of obesity and 11% for diabetes (overwhelmingly Type 2)
If the drugs are directly both improving weight reduction and cancer reduction, then we need to double down. Ganta wonders the same thing about the drugs apparent positive effects on several conditions, from dementia to sleep apnea: Is it that obesity is causing or contributing to the problem [and that weight loss is causing the improvement], or is the medication directly having an impact through a different mechanism? She hopes there will be more research to parse this out in the years to come
A bathroom counter drawer or a small organizer box in the kitchen works